GSK3B polymorphisms alter transcription and splicing in Parkinson's disease

Annals of Neurology

Volumn 58, Issue 6, 2005, Pages 829-839

  Kwok, John B J ^a,b   Hallupp, Marianne ^a   Loy, Clement T ^a,b   Chan, Daniel K Y ^b,c   Woo, Jean ^d   Mellick, George D ^e   Buchanan, Daniel D ^e   Silburn, Peter A ^e   Halliday, Glenda M ^b,f   Schofield, Peter R ^a,b,f  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; TAU PROTEIN;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; EXON; FEMALE; GENE; GENE INTERACTION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC TRANSCRIPTION; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN CELL; INTRON; MAJOR CLINICAL STUDY; MALE; MAPT GENE; PARKINSON DISEASE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RNA SPLICING; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; BRAIN; COHORT STUDIES; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLYCOGEN SYNTHASE KINASE 3; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; LYMPHOCYTES; MALE; PARKINSON DISEASE; PHOSPHORYLATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); RISK FACTORS; RNA SPLICING; TAU PROTEINS; TRANS-ACTIVATION (GENETICS);

EID: 28544435240     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20691     Document Type: Article

References (32)

1. Sethi KD. Clinical aspects of Parkinson disease. Curr Opin Neurol 2002;15:457-460.
2. Shahani N, Brandt R. Functions and malfunctions of the tau proteins. Cell Mol Life Sci 2002;59:1668-1680.
3. Martin ER, Scott WK, Nance M, et al. Association of single-nucleotide polymorphisms of the Tau gene with late-onset Parkinson disease. JAMA 2001;286:2245-2250.
4. Maraganore DM, Hernandez DG, Singleton AB, et al. Case-control study of the extended Tau gene haplotype in Parkinson's disease. Ann Neurol 2001;50:658-661.
5. Golbe LI, Lazzarini AM, Spychala JR, et al. The Tau A0 allele in Parkinson disease. Mov Disord 2001;16:442-447.
6. Pastor P, Ezquerra M, Munoz E, et al. Significant association between the tau gene A0/A0 genotype and Parkinson's disease. Ann Neurol 2000;47:242-245.
7. Kwok JBJ, Teber ET, Loy C, et al. Tau haplotypes regulate transcription and are associated with Parkinson's disease. Ann Neurol 2004;55:329-334.
8. Healy DG, Abou-Sleiman PM, Lees AJ, et al. Tau gene and Parkinson's disease: a case-control study and meta-analysis. J Neurol Neurosurg Psychiatry 2004;75:962-965.
9. Jope R, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004;29:95-102.
10. Scott WK, Nance MA, Watts RL, et al. Complete genomic screen in Parkinson's disease. JAMA 2001;286:2239-2244.
11. Schaffer B, Wiedau-Pazos M, Geschwind DH. Gene structure and alternative splicing of glycogen synthase kinase-3 beta (GSK-3β) in neural and non-neural tissues. Gene 2003;302:73-81.
12. Fraser E, Young N, Dajani R, et al. Identification of the Axin and FRAT binding region of glycogen synthase kinase-3. J Biol Chem 2002;277:2176-2185.
13. Mukai F, Ishiguro K, Sano Y, Fujita SC. Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3β. J Neurochem 2002;81:1073-1083.
14. Buchanan DD, Silburn PA, Chalk JB, et al. The Cys282Tyr polymorphism in the HFE gene in an Australian Parkinson's disease patient. Neurosci Lett 2002;327:91-94.
15. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol 1992;32:S125-S127.
16. Chan DKY, Lam MKP, Hung WT, Wilcken DEL. Strong association between N-acetyltransferase 2 genotype and PD in Hong Kong Chinese. Neurology 2003;60:1002-1005.
17. Maranganore DM, Harding AE, Marsden CD. A clinical and genetic study of familial Parkinson's disease. Mov Disord 1991;6:205-211.
18. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
19. Russ C, Lovestone S, Powell JF. Identification of sequence variants and analysis of the role of the glycogen synthase 3 beta gene and promoter in later onset Alzheimer's disease. Mol Psychiatry 2001;6:320-324.
20. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-265.
21. Stanford PM, Halliday GM, Brooks WS, et al. Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by tau mutations. Brain 2000;123:880-893.
22. Cote J, Dupuis S, Wu JY. Polypyrimidine track-binding protein binding downstream of caspase-2 alternative exon 9 represses its inclusion. J Biol Chem 2001;276:8535-8545.
23. Quandt K, Frech K, Wingender E, Werner T. Matind and Matinspector-New fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 1995;23:4878-4884.
24. Devlin B, Risch NA. Comparison of linkage disequilibrium measures for fine-scale mapping. Genomics 1995;29:311-322.
25. Weiss KM, Clarke AG. Linkage disequilibrium and the mapping of complex human traits. Trends Genet 2002;18:19-24.
26. Mamah CE, Lesnick TG, Lincoln SJ, et al. Interaction of α-synuclein and Tau genotypes in Parkinson's disease. Ann Neurol 2005;57:439-443.
27. Lucas JJ, Hernandez F, Gomez-Ramos P, et al. Decreased nuclear β-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice. EMBO J 2001;20:27-39.
28. Spittaels K, Van den Haute C, Van Dorpe J, et al. Glycogen synthase kinase-3β phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. J Biol Chem 2000;275:41340-41349.
29. Evans E, Fung HC, Steele J et al. The tau H2 haplotype is almost exclusively Caucasian in origin. Neurosci Lett 2004;369:183-185.
30. Geschwind DH. Tau phosphorylation, tangles, and neurodegeneration: the chicken or the egg? Neuron 2003;40:457-460.
31. Goldbaum O, Richter-Landsberg C. Activation of PP2A-like phosphatase and modulation of Tau phosphorylation accompany stress-induced apoptosis in cultured oligodendrocytes. Glia 2002;40:271-282.
32. Lecamwasam D, Synek B, Moyles K, Ghose K. Chronic lithium neurotoxicity presenting as Parkinson's disease. Int Clin Psychopharmacol 1994;9:127-129.